Wedbush reiterates Outperform rating on Zenas BioPharma, $45 price target

Wedbush reiterated their Outperform rating on Zenas BioPharma's stock with a price target of $45.00.The price target implies an upside of 68.2% from the Sep 29 close of $26.76.Key takeaways from the analyst noteDifferentiated Safety Profile: Obexelimab's design as a bifunctional monoclonal antibody…